JNK inhibitors for the treatment of neurological disorders

Details JNK inhibitors for the treatment of neurological disorders JNK inhibitors for the treatment of neurological disorders

2002-01-09

2008-11-18

Saucier, Sandra E (Department: 1651)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving transferase

C435S194000

Reexamination Certificate

active

07452686

ABSTRACT:
The present invention describes methods for identifying compounds that inhibit JNK and MLK kinase activity as drugs for treating a mammal susceptible to or having a neurological condition. This invention also discloses methods for preventing neuronal cell death and treating neurological conditions that involve neuronal cell death, particularly neurodegenerative diseases characterized by glutamine or kainate mediated toxicity, such as Huntington's disease and Alzheimer's disease.

REFERENCES:
patent: 4980281 (1990-12-01), Housey
patent: 5385915 (1995-01-01), Buxbaum et al.
patent: 5461146 (1995-10-01), Lewis et al.
patent: 5468872 (1995-11-01), Glicksman et al.
patent: 5475110 (1995-12-01), Hudkins et al.
patent: 5516772 (1996-05-01), Glicksman et al.
patent: 5534426 (1996-07-01), Karin et al.
patent: 5554523 (1996-09-01), Reddy et al.
patent: 5591855 (1997-01-01), Hudkins et al.
patent: 5593884 (1997-01-01), Karin et al.
patent: 5594009 (1997-01-01), Hudkins et al.
patent: 5605808 (1997-02-01), Karin et al.
patent: 5621100 (1997-04-01), Lewis et al.
patent: 5621101 (1997-04-01), Lewis et al.
patent: 5676945 (1997-10-01), Reddy et al.
patent: 5705511 (1998-01-01), Hudkins et al.
patent: 5741808 (1998-04-01), Lewis et al.
patent: 5750555 (1998-05-01), Trostmann et al.
patent: 5756494 (1998-05-01), Lewis et al.
patent: 5817479 (1998-10-01), Au-Young et al.
patent: 6060247 (2000-05-01), Miller et al.
patent: 6087366 (2000-07-01), Park et al.
patent: 6127401 (2000-10-01), Singh et al.
patent: 6159948 (2000-12-01), Robertson et al.
patent: 6455525 (2002-09-01), Singh et al.
patent: 6514745 (2003-02-01), Karin et al.
patent: 6943000 (2005-09-01), Davis et al.
patent: 2002/0028815 (2002-03-01), Ator et al.
patent: 2002/0061920 (2002-05-01), Gingrich et al.
patent: 2002/0198219 (2002-12-01), Grant et al.
patent: 2148898 (1995-05-01), None
patent: WO 93/15201 (1993-08-01), None
patent: WO 94/17498 (1994-08-01), None
patent: WO 95/03324 (1995-02-01), None
patent: WO 95/23849 (1995-09-01), None
patent: WO 9918193 (1999-04-01), None
patent: WO 99/58982 (1999-11-01), None
patent: WO 00/13015 (2000-03-01), None
patent: WO 00/47583 (2000-08-01), None
patent: WO 02/14536 (2002-02-01), None
Qin et al., “Nuclear Factor-κB Contributes to Excitotoxin-Induced Apoptosis in Rat Striatum” (Jan. 1998) Mol. Pharmacol., 53, 33-42.
Liu et al., “Expression of the Huntingtin Mutant Activates JNK/SAPK and Induces Neuronal Apoptosis” (Oct. 1997) Society for Neuroscience, 23(1-2), 1909, Abstract 741.1.
Fadeel et al. :Apoptosis in Human Disease: A New Skin for the Old Ceremony Biochem. Biophys. Res. Comm. (1999) 266: 699-717.
Haun et al. “CEP-1347 prevents excitotoxin-induced death of neurons in basal forebrain: A quantitative retrograde labeling study in adult rat” Soc. Neurosci. (1996) 22: 741, abstract only.
Finiels et al. “Induction of neuronal apoptosis by exitotoxins associated with long-lasting increase of 12-O-tetradecanoylphorbol 13-acetate-responsive element-binding activity” J. Neurochem (1995) 65: 1027-1034.
Borasio et al. “CEP-1347/KT515, a JNK pathway inhbitor, supports the in vitro survival of chick embryonic neurons” NeuroReport (Apr. 1998) 9(7): 1435-1439.
Liu et al. “Neuronal and glial apoptosis after traumatic spinal cord injury” J. Neurosci. (Jul. 1997) 17(14): 5395-5406.
Maas et al. “Apoptosis of central and peripheral neurons can be prevented with cyclin-dependement kinase/mitogen-activated protein kinase inhbitors” J. Neurochem (Apr. 1998) 70: 1401-1410.
Gnegy et al. “Regulation of transsynaptically elicited increases of 3′:5′-cyclic AMP by endogenous phosphodiesterase activitr” Proc. Nat. Acad. Sci. USA (1976) 73(2): 352-355.
Yang et al. “Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the JNK3 gene” Nature (1997) 389: 865-870.
Park et al. “Ordering the cell death pathway” J. Biol. Chem. (1996) 271(36): 21898-21905.
Park et al. “Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons” J. Biol. Chem. (1996) 271(14): 8161-8169.
Reynolds et al. “Stress-activated protein kinase/c-Jun N-terminal kinase phosphorylates tau protein” J. Neurochem. (1997): 1736-1744.
Anderson, A. J. et al. DNA Damage and Apoptosis in Alzheimer's Disease: Colocalization with c-Jun Immunoreactivity, Relationship to Brain Area, and Effect of Postmortem Delay.J. Neurosci. 16, 1710-1719 (Mar. 1, 1996).
Bossy-Wetzel, E. et al. Induction of Apoptosis by the Transcription Factor c-Jun.EMBO J. 16, 1695-1709 (1997).
Chen, Y. et al. The Role of c-Jun N-Terminal Kinase (JNK) in Apoptosis Induced by Ultraviolet C and y Radiation.J. Biol. Chem. 271, 31929-31936 (Dec. 13, 1996).
Cheung, N. S. et al. Kainate-induced apoptosis correlates with c-Jun activation in cultured cerebellar granule cells.J Neurosci Res. 52, 69-82 (Apr. 1, 1998).
David, G. et al. Cloning of the SCA7 Gene Reveals a Highly Unstable CAG Repeat Expansion.Nature Genetics17, 65-70 (Sep. 1997).
Gupta et al, Human JNK3 Alpha 2 Protein Kinase (JNK3A2) mRNA.GenBankAccession No. U34819.
Gupta et al. Human JNK3 Alpha 2 Protein Kinase (JNK3A2) mRNA.GenBankAccession No. U33820.
Davis, R. J. MAPKs: New JNK Expands the Group.TIBS19, 470-473 (Nov. 1994).
Derijard, B. et al. JNK1: A Protein Kinase Stimulated by UV Light and Ha-Ras That Binds and Phosphorylates the c-Jun Activation Domain.Cell76, 1025-1037 (Mar. 25, 1994).
Dickens, M. et al. A Cytoplasmic Inhibitor of JNK Signal Transduction Pathway.Science277, 693 (Aug. 1, 1997).
Dorow, Donna S. et al. Complete Nucleotide Sequence, Expression, and Chromosomal Localization of Human Mixed-Lineage Kinase 2.Eur. J. Biochem. 234, 492-500, (1995).
Duyao, M. et al. Trinucleotide Repeat Length Instability and Age of Onset in Huntington's Disease.Nature Genetics4, 387-392 (Aug. 1993).
Eilers, A. et al. Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons.J. Neurosci. 18, 1713-1724 (Mar. 1, 1998).
Gallo, K. A. et al. Identification and Characteristics of SPRK, a Novel src-Homology 3 Domain-containing Proline-rich Kinase with Serine/Threoine Kinase Activity.J. Biol. Chem. 269, 15092-15100 (May 27, 1994).
Goodenough et al.Society for Neurological Abstracts23, 1387 (Oct. 1997).
Gupta, S. et al. Selective Interaction of JNK Protein Kinase Isoforms with Transcription Factors.EMBO J. 15, 2760-2770 (1996).
Ham, J. et al. A c-Jun Dominant Negative Mutant Protects Sympathetic Neurons against Programmed Cell Death.Neuron. 14, 927-939 (May 1995).
Herdegen, T. et al. Lasting N-Terminal Phosphorylation of c-Jun and Activation of c-Jun N-Terminal Kinases after Neuronal Injury.J. Neurosci. 18, 5124-5135 (Jul. 15, 1998).
Hirai, S. et al. MST/MLK2, a Member of the Mixed Lineage Kinase Family, Directly Phosphorylates and Activates SEK1, an Activator of c-Jun N-terminal Kinase/Stress-activated Protein Kinase.J. Biol. Chem. 272, 15167-15173 (Jun. 13, 1997).
The Huntington's Disease Collaborative Research Group. A Novel Gene Containing a Trinucleotide Repeat that is Expanded and Unstable on Huntington's Disease Chromosomes.Cell72, 971-983 (Mar. 26, 1993).
Kyriakis, J. M. et al. The Stress-Activated Protein Kinase Subfamily of c-Jun Kinases.Nature369, 156-160(May 12, 1994).
Lin, A. et al. Identification of a Dual Specificity Kinase that Activates the Jun Kinases and p38-Mpk2.Science268, 286-290 (Apr. 14, 1995).
Liu, Ya Fang. Expression of Polyglutamine-expanded Huntington Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line.J. Biol. Chem. 273, 28873-77 Oct. 30, 1998.
Liu, Ya Fang et al. Expression of the Huntington Mutant Activates JNK/SAPK and Induces Neuronal Apoptosis.Society for Neurosci. Abstracts23, 1909 (Oct. 25, 1997)—Abstract XP002115942.
Liu, Ya Fang et al. SH3 Domain-dependent Association of Huntington with Epidermal Growth Factor Receptor Signaling Complexes.J

Affiliated with

Also associated with

Rating

JNK inhibitors for the treatment of neurological disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with JNK inhibitors for the treatment of neurological disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and JNK inhibitors for the treatment of neurological disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4039274